Current NIH-funded bench research programs are focused on neurodevelopment and neonatal neuroprotection using state of the art techniques including brain imaging. We use a variety of animal models, from rodents to non-human primates to determine the effects of neonatal stress and neurotropic drugs on the developing brain and to test the safety and efficacy of erythropoietin (Epo) as a neuroprotective therapy. The overarching research goal of the Division is to improve the neurodevelopmental outcomes of at-risk infants. Clinical research is focused on trials of Epo neuroprotection in preterm and asphyxiated infants, evaluation of sedative drugs in the setting of extreme prematurity and asphyxia, prevention of BPD, biomedical informatics, and medical education including the use of newborn infant simulators, as well as global neonatal-perinatal health and epidemiologic research. With the 2011 addition of senior scientist faculty member, Dr. Colin Studholme, we have additional expertise in brain imaging with which to evaluate our neuroprotective strategies. In 2013, Dr. Sunny Juul was awarded a $9 million UO1 grant supporting a 5-year multi-center clinical trial investigating Epo as a neuroprotective agent in extremely preterm infants.
For more information on this specialty, please visit the Neonatology webpage.